Introduction.- Epidemiology.- Clinical trial design, endpoints and regulatory requirements. Biomarkers HFpEF/HFrEF. Imaging Technologies / MRI and Echo. Comorbidities in HF. Current Guideline based therapy of HFreF and HFpEF. New and Emerging Therapies and Targets. Ivabradine.- Beta3 agonists.- Novel MRAs.- pGCs and Natriuretic peptides.- sGC stimulators.- PDE’s.- Adenosin and A1 Agonists.- Myosin heavy chain / Troponin.- Stem cells.- Diuretics and Vasopressin.- GeneTherapy.- RNA-based therapies and micro RNAs.- Cardiac myosin activation using gene therapy.- Bendavia – mitochondrial therapies.- WNT signaling.- Anticoagulation therapy and NOACS in HF.- Potassium Binders.- Iron.